FierceBiotech

Virtually the Same Percentage of Surveyed Rheumatologists Selected Enbrel and Humira as the Most Efficacious Agent for the

However, a Slightly Higher Percentage of Surveyed MCO Pharmacy Directors Selected Humira Over Enbrel As the Most Efficacious Rheumatoid Arthritis Therapy, According to Findings from Decision Resources ...
Los Angeles Times

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...
The Boston Globe

Low-cost versions of Humira, the nation’s top-selling drug, are off to a sluggish start

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...
Seeking Alpha

AbbVie: Comeback Expected After Humira Patent Expiration

AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug ...